RxSight Reports Fourth Quarter and Fiscal Year Financial Results
Published on February 27, 2026
ALISO VIEJO, Calif.—RxSight, Inc., (Nasdaq: RXST) an ophthalmic medical device company focused on improving vision after cataract surgery, late Wednesday announced financial results for the fourth quarter and full year ended December 31, 2025. Full-year 2025 global sales decreased 4 percent to $134.5 million compared with the previous year, the company reported, consistent with the preliminary figures shared in January. Revenue from sales of light adjustable lenses (LAL), clocking in at 109,615 units, increased by 12 percent, but was offset by a 48 percent decrease in light delivery devices LDD system sales versus the prior year period.